Neuphoria Therapeutics (NEUP) Other Accumulated Expenses (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Other Accumulated Expenses of $169666.0 for Q1 2026, up 414.23% year-over-year from $32994.0 in Q1 2025, and up 505.76% quarter-over-quarter from $28009.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Other Accumulated Expenses (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Other Accumulated Expenses for 4 consecutive years, with $169666.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 414.23% year-over-year to $169666.0; the TTM figure through Mar 2026 stood at $169666.0 (up 414.23% YoY), while the FY2025 annual figure was $35756.0, down 88.51% from the prior year.
- Other Accumulated Expenses climbed to $169666.0 in Q1 2026 per NEUP's latest filing, from $28009.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $311172.0 in Q2 2024 and bottomed at $28009.0 in Q4 2025.
- Historically, Other Accumulated Expenses has averaged $95292.0 across 4 years, with a median of $37580.5 in 2023.
- Annual changes were most pronounced in 2024 — Other Accumulated Expenses soared 689.68% — and 2025, when it plunged 88.51%.
- Neuphoria Therapeutics' Other Accumulated Expenses stood at $39405.0 in 2023, then dropped by 15.48% to $33306.0 in 2024, then slipped by 15.9% to $28009.0 in 2025, then surged by 505.76% to $169666.0 in 2026.
- Business Quant data shows NEUP's Other Accumulated Expenses at $169666.0 in Q1 2026, $28009.0 in Q4 2025, and $112028.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 169,666.00 |
| Dec 31, 2025 | 28,009.00 |
| Sep 30, 2025 | 112,028.00 |
| Jun 30, 2025 | 35,756.00 |
| Mar 31, 2025 | 32,994.00 |
| Sep 30, 2024 | 33,306.00 |
| Jun 30, 2024 | 311,172.00 |
| Jun 30, 2023 | 39,405.00 |